Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study

•A phase I study of JR-142, a novel long-acting growth hormone, found its weekly injections of 0.15 to 1.0 mg/kg for up to four weeks safe and well tolerated, with a dose-dependent increase in the plasma concentrations of JR-142 and serum IGF-1. JR-142 demonstrated a unique ability to maintain IGF-1 levels in a more favorable range than other long-acting GH therapeutics.•These findings need to be substantiated in pediatric GHD patients to establish JR-142 as a useful new therapeutic for long-term treatment.